Search

Junior membership

If you're at an early stage in your career, junior membership can be a great way to:

Expand your knowledge
Make connections
Access EHA's early career opportunities
Stay up to date with the latest developments
As a junior member, you can also apply for EHA…

Read more

Emeritus membership

If you're a scientific researcher, physician, or healthcare-affiliated professional who's now retired or is close to retirement, you can join EHA at a reduced rate.

Read more

Deadlines & Announcements

New announcements will be published as soon as new elements for the Congress Sponsor Program for EHA2025 are released.

Read more

Publications

Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Ocul Surf. 2019 Jan 7.

Read more

Choose your membership

Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.

Read more

Target audience

You are a hematologist working at an academic center or a large community hospital that is known for running clinical trials.

Read more

Chairs and Members

Chair (2017-present)Oliver A. Cornely—University Hospital Cologne, Cologne (Germany)

Co-chair (2023-present)Livio Pagano—Fondazione Policlinico A.

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

Selected EMA news

March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab) 
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines 
Calquence (acalabrutinib) - new indication
Treatment of blood cancer

Columvi (glofitamab) - new indication
Treatment of blood cancer

Darzalex (daratumumab) - change of indication
Treatment…

Read more